Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 117-128

  Lin, Yin Ku ^a,b   Huang, Zih Rou ^a   Zhuo, Rou Zi ^a   Fang, Jia You ^a,c  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Calcipotriol; Methotrexate; Nanostructured lipid carriers; Psoriasis; Topical delivery

Indexed keywords

CALCIPOTRIOL; GLYCEROL PALMITOSTEARATE; LIPID; METHOTREXATE; NANOMATERIAL; SQUALENE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; FEMALE; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PSORIASIS; SKIN IRRITATION; SKIN PERMEABILITY; TOXICITY TESTING;

ADMINISTRATION, TOPICAL; ANIMALS; CALCITRIOL; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; DRUG COMPOUNDING; FEMALE; LIPIDS; METHOTREXATE; MICE; MICE, NUDE; NANOCAPSULES; PARTICLE SIZE; SKIN ABSORPTION;

EID: 77951186087     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866-872.
2. Su YH, Fang JY. Drug delivery and formulations for the topical treatment of psoriasis. Expert Opin Drug Deliv. 2008;5:235-249.
3. Vakirlis E, Kastanis A, Ioannides D. Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. Ther Clin Risk Manage. 2008;4:141-148.
4. Witman PM. Topical therapies for localized psoriasis. Mayo Clin Proc. 2001;76:943-949.
5. van der Kerkhof PCM, Cambazard F, Hutchinson PE, et al. The effect of addition of calcipotriol ointment (50 μg/g) to acitretin therapy in psoriasis. Br J Dermatol. 1998;138:84-89.
6. 3-based conjugates for topical treatment of psoriasis: synthesis, antiproliferative activity, and cutaneous penetration studies. Pharm Res. 2005;22:50-57.
7. ®) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol. 2002;46:907-913.
8. Fogh K, Kragballe K. New vitamin D analogs in psoriasis. Curr Drug Target Inflamm Allergy. 2004;3:199-204.
9. 3 analogues is not inactivated by subsequent UV exposure. Photodermatol Photoimmunol Phatomed. 2008;24:16-18.
10. Pople PV, Singh KK. Development and evaluation of topical formulation containing solid lipid nanoparticles of vitamin A. AAPS Pharm Sci Tech. 2006;7:E1-E7.
11. Mandawgade SD, Patravale VB. Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int J Pharm. 2008;363:132-138.
12. Müller RH, Petersen RD, Hommoss A, Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev. 2007;59:522-530.
13. de Jong EMGJ, Mørk NJ, Seijger MMB, et al. The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial. Br J Dermatol. 2003;148:318-325.
14. Demerjian M, Mao MQ, Choi EH, et al. Topical treatment with thiazolidinediones, activators of peroxisome proliferators-activated receptor;, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp Dermatol. 2006;15:154-160.
15. Ilic L, Gowrishankar TR, Vaughan TE, Herndon TO, Weaver JC. Spatially constrained skin electroporation with sodium thiosulfate and urea creates transdermal microconduits. J Control Release. 1999;61:185-202.
16. Jenning V, Thünemann AF, Gohla SH. Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm. 2000;199:167-177.
17. Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm. 2008;70:633-640.
18. Puglia C, Blasi P, Rizza L, et al. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int J Pharm. 2008;357:295-304.
19. Wissing SA, Müller RH. Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration. J Control Release. 2002;81:225-233.
20. Weyenberg W, Filev P, Van den Plas D, et al. Cytotoxicity of submicron emulsions and solid lipid nanoparticles for dermal application. Int J Pharm. 2007;337:291-298.
21. Jores K, Haberland A, Wartewig S, Mäder K, Mehnert W. Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by spectrofluorometry and Raman spectroscopy. Pharm Res. 2005;22:1887-1897.
22. Lombardi Borgia S, Regehly M, Sivaramakrishnan R, et al. Lipid nanoparticles for skin penetration enhancement correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Control Release. 2005;110:151-163.
23. Baroli B, López-Quintela MA, Delgado-Charro MB, Fadda AM, BlancoMéndez J. Microemulsions for topical delivery of 8-methoxsalen. J Control Release. 2000;69:209-218.
24. Dubey V, Mishra D, Dutta T, Nahar M, Saraf DK, Jain NK. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release. 2007;123:148-154.
25. Venkateswarlu V, Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release. 2004;95:627-638.
26. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161-177.
27. Jenning V, Schäfer-Korting M, Gohla S. Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties. J Control Release. 2000;66:115-126.
28. Bunjes H, Drechsler M, Koch MHJ, Westesen K. Incorporation of the model drug ubidecarenone into solid lipid nanoparticles. Pharm Res. 2001;18:287-293.
29. Hu FQ, Jiang SP, Du YZ, Yuan H, Ye YQ, Zeng S. Preparation and characteristics of monostearin nanostructured lipid carriers. Int J Pharm. 2006;314:83-89.
30. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54:S131-S155.
31. Chen H, Chang X, Du D, et al. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Control Release. 2006;110:296-306.
32. Küchler S, Radowski MR, Blaschke T, et al. Nanoparticles for skin penetration enhancement a comparison of a dendritic core-multishellnanotransporter and solid lipid nanoparticles. Eur J Pharm Biopharm. 2009;71:243-250.
33. ®) for cutaneous drug delivery: structure, protection and skin effects. J Biomed Nanotechnol. 2007;3:317-331.
34. Bourke JF, Berth-Jones J, Hutchinson PE. Occlusion enhances the efficacy of topical calcipotriol in the treatment of psoriasis vulgaris. Clin Exp Dermatol. 1993;18:504-506.
35. Nielsen PG. Calcipotriol or clobetasol propionate occluded with a hydrocolloid dressing for treatment of nummular psoriasis. Acta Derm Venereol. 1993;73:394.
36. Alvarez-Figueroa MJ, Blanco-Méndez J. Transdermal delivery of methotrexate: iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int J Pharm. 2001;215:57-65.
37. Schäfer-Korting M, Mehnert W, Korting H. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev. 2007;59:427-443.
38. Kogan A, Garti N. Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interf Sci. 2006;123-126:369-385.
39. Wong TW, Chen CH, Huang CC, Lin CD, Hui SW. Painless electroporation with a new needle-free microelectrode array to enhance transdermal drug delivery. J Control Release. 2006;110:557-565.
40. Zhao K, Singh J. In vitro percutaneous absorption enhancement of propranolol hydrochloride through porcine epidermis by terpenes/ethanol. J Control Release. 1999;62:359-366.
41. Serup J, Agner T. Colorimetric quantification of erythema a comparison of two colorimeters (Lange Micro Color and Minolta Chroma Meter CR-200) with a clinical scoring scheme and laser-Doppler flowmetry. Clin Exp Dermatol. 1990;15:267-272.